XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.21.1

Stock Incentive Plans | 3 Months Ended
--- | ---
Mar. 31, 2021
Share-based Payment Arrangement [Abstract] |
Stock Incentive Plans | Stock Incentive Plans The Company recorded shared-based compensation expense as follows for the three months ended March 31, 2021 and 2020 (in thousands):
| Three Months Ended
| March 31, 2021 |  | March 31, 2020
Salaries, wages and employee benefits - continuing operations | $ | 2,269 |  |  | $ | 2,817 |
Salaries, wages and employee benefits - discontinued operation | 16 |  | 188
Total share-based compensation expense | $ | 2,285 |  |  | $ | 3,005 |
Stock Incentive Plan In May 2016, the Company adopted the 2016 Omnibus Incentive Compensation Plan (the “Omnibus Plan”) for the issuance of up to 2,000 common shares. As of March 31, 2021, approximately 793 shares remain available for grant under the Omnibus Plan. Stock Options Share-based compensation expense associated with stock options is amortized ratably over the requisite service period. The Company estimates the fair value of the grants using the Black-Scholes option-pricing model. Stock option transactions during the three months ended March 31, 2021 on a continuing operations basis were as follows:
| Stock Options |  | Weighted-Average Exercise Price
Outstanding as of December 31, 2020 | 359 |  |  | $ | 55.79 |
Granted | 39 |  |  | 75.05 |
Exercised | (26) |  |  | 54.26 |
Forfeited | — |  |  | — |
Outstanding as of March 31, 2021 | 372 |  |  | $ | 58.06 |
As of March 31, 2021, the total share-based compensation expense related to unvested stock options net yet recognized was approximately $1,250, and the weighted average period over which it is expected to be recognized is approximately two years. Stock option transactions during the three months ended March 31, 2021 on a discontinued operation basis were as follows:
| Stock Options |  | Weighted-Average Exercise Price
Outstanding at December 31, 2020 | 14 |  |  | $ | 52.15 |
Granted | — |  |  | — |
Exercised | (14) |  |  | 52.15 |
Forfeited | — |  |  | — |
Outstanding at March 31, 2021 | — |  |  | $ | — |
Restricted Shares Restricted shares are restricted from sale or transfer until vesting, and restrictions lapse in three equal installments beginning one year after the date of grant. Share-based compensation expense associated with these awards is amortized ratably over the requisite service period. Restricted share transactions during the three months ended March 31, 2021 on a continuing operations basis were as follows:
| Restricted Shares |  | Weighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020 | 213 |  |  | $ | 62.78 |
Granted | 108 |  |  | 75.14 |
Vested | (96) |  |  | 61.38 |
Forfeited | (11) |  |  | 69.13 |
Outstanding as of March 31, 2021 | 214 |  |  | $ | 69.31 |
As of March 31, 2021, the total share-based compensation expense related to the restricted shares net yet recognized was approximately $13,179, and the weighted-average period over which it is expected to be recognized is approximately two years. Restricted share transactions during the three months ended March 31, 2021 on a discontinued operation basis were as follows:
| Restricted Shares |  | Weighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020 | 8 |  |  | $ | 60.83 |
Granted | — |  |  | — |
Vested | (4) |  |  | 61.78 |
Forfeited | (4) |  |  | 61.37 |
Outstanding as of March 31, 2021 | — |  |  | $ | — |
Performance Awards Performance awards are based on achieving certain financial targets, such as targets for earnings before interest, taxes, depreciation and amortization, and the Company’s total shareholder return as compared to the total shareholder return of a selected peer group, as determined by the Company’s Board of Directors. Performance targets are set at the beginning of each three-year measurement period. Share-based compensation expense associated with these awards is amortized ratably over the vesting period. Depending on the financial target, the compensation expense is based on the projected assessment of the level of performance that will be achieved. Performance award transactions during the three months ended March 31, 2021 on a continuing operations basis were as follows assuming target levels of performance:
| Performance Awards |  | Weighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020 | 65 |  |  | $ | 67.62 |
Granted | 36 |  |  | 87.33 |
Earned | (11) |  |  | 92.89 |
Forfeited | (11) |  |  | 70.22 |
Outstanding as of March 31, 2021 | 79 |  |  | $ | 75.61 |
As of March 31, 2021, the total share-based compensation expense related to unearned performance awards not yet recognized, assuming the Company's current projected assessment of the level of performance that will be achieved, was approximately $3,652, and the weighted-average period over which it is expected to be recognized is approximately three years. Employee Stock Purchase Plan Under the 2005 Employee Stock Purchase Plan (the “ESPP”), the Company is authorized to issue up to a remaining 335 shares of common stock to employees. These shares may be issued at a price equal to 90% of the lesser of the market value on the first day or the last day of each six-month purchase period. Common stock purchases are paid for through periodic payroll deductions and/or up to two large lump sum contributions. No shares were issued during the three months ended March 31, 2021.
Director Restricted Shares Under the Amended and Restated Non-Employee Director Stock Plan (the “Amended Plan”), approved in May 2007 and further amended in February 2013 and January 2016, up to 360 common shares may be issued. As of March 31, 2021, approximately 90 shares remain available for grant under the Amended Plan. Director restricted share transactions during the three months ended March 31, 2021 were as follows:
| Director Restricted Shares |  | Weighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020 | 24 |  |  | $ | 43 |
Granted | 2 |  |  | 93 |
Vested | — |  |  | — |
Forfeited | — |  |  | — |
Outstanding as of March 31, 2021 | 26 |  |  | $ | 47 |
For the three-months ended March 31, 2021 and 2020, the Company recorded $328 and $261, respectively, of share-based compensation expense associated with these grants. As of March 31, 2021, the total share-based compensation expense related to the restricted shares net yet recognized was approximately $256.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration